Research ArticleCancer

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

See allHide authors and affiliations

Science Translational Medicine  30 Nov 2016:
Vol. 8, Issue 367, pp. 367ra166
DOI: 10.1126/scitranslmed.aag3187

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Running interference

Interleukin-2 (IL-2) binds to receptors on multiple different types of T cells. CD8 T cells, which can kill tumor cells, have IL-2 receptors with two subunits. When IL-2 binds to these, it promotes the T cells’ activation. In contrast, regulatory T cells dampen the antitumor immune response, and they express a different type of IL-2 receptor, which contains CD25 in addition to the other two subunits. CD25 binds IL-2 tightly but does not signal. To address this, Arenas-Ramirez et al. developed an anti–IL-2 antibody that can block CD25, such that delivering the antibody together with IL-2 allows IL-2 to bind specifically to the two-subunit IL-2 receptors and promote an antitumor immune response without interference from regulatory T cells.